Ledger.Open graph →
SEC Form D · filed February 24, 2021

Orchard Therapeutics plc

Offering
$150.0M
Sold
$150.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
LONDON, United Kingdom
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (20)

Steven E. Altschuler · LONDON, United KingdomDirectorJohn T. Curnutte · LONDON, United KingdomDirectorFrank E. Thomas · LONDON, United KingdomExecCharles A. Rowland Jr · LONDON, United KingdomDirectorAlicia A. Secor · LONDON, United KingdomDirectorJon T. Ellis · LONDON, United KingdomDirectorJames A. Geraghty · Cambridge, MADirectorJoanne T. Beck · LONDON, United KingdomDirectorBobby Gaspar · LONDON, United KingdomExec · DirectorMarc T. Dunoyer · LONDON, United KingdomDirectorSteven E. Altschuler · LONDON, United KingdomDirectorFrank E. Thomas · LONDON, United KingdomExecJohn T. Curnutte · LONDON, United KingdomDirectorCharles A. Rowland Jr · LONDON, United KingdomDirectorAlicia A. Secor · LONDON, United KingdomDirectorJon T. Ellis · LONDON, United KingdomDirectorJames A. Geraghty · LONDON, United KingdomDirectorJoanne T. Beck · LONDON, United KingdomDirectorBobby Gaspar · LONDON, United KingdomExec · DirectorMarc T. Dunoyer · LONDON, United KingdomDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗